Industry Explorers Blaze On

  1. I-MAK's Quest To Trim The Biopharmaceutical Patent Thicket 7/3/2023

    I-MAK, a nonprofit focused on reforming the drug patent system, is bringing patients into the patent system to advocate against abuses that keep affordable drugs out of reach.

  2. Debunking BYOD Myths In Clinical Trials 7/3/2023

    By adopting BYOD, life sciences can expand the collection of quality data sets during clinical trials to drive the development and approval of life-changing therapies for the patients that need them.

  3. Your Consultants, Your Destiny 7/3/2023

    Have consultants become more important than ever in pharma manufacturing? Louis Garguilo, Chief Editor, Outsourced Pharma, talks with three experts who have strong opinions on this question.

  4. What Life Sciences Startups Can Do About Market Swings 7/3/2023

    Ongoing capital needs that can span a decade or more mean that life sciences companies need the ability to navigate every season of market conditions. This requires strategic and long-term planning — and possibly some out-of-the-box thinking to ensure consistent funding well into the future.

  5. Companies To Watch: Kinaset Therapeutics 7/3/2023

    Kinaset Therapeutics is moving fast in the respiratory space to advance a potential first-time therapy.

  6. Given The Increase In Size Of The Industry And The Challenge Of Fundraising, Are There Other Ways To Think About Raising Capital? 7/3/2023

    See the answer from Dennis Purcell, founder and senior advisor at Aisling Capital.

  7. Facing The Drug Launch Challenge As A New CEO 7/3/2023

    Economic instability, geopolitical struggles, market access, pricing, and regulatory differences — among many other issues — can present themselves at any time before, during, or after the launch. What is important is how a CEO manages the steps toward launch success.

  8. Cell & Gene Therapies Manufacturing Market Outlook 7/3/2023

    In ISR’s Cell & Gene Therapies Manufacturing Market Outlook (2nd Edition), we asked respondents to rank their top three satisfaction drivers regarding a CDMO’s performance in cell and/or gene manufacturing activities.

  9. India's CROs & CDMOs Come Of Age In The Global Marketplace 7/3/2023

    While a low price is the initial attraction for many American and European companies looking at India’s life sciences ecosystem, there are many additional factors that can be more meaningful.

  10. What Strategies Can Biotech Executives Use To Effectively Prioritize And De-Risk Development Programs During Tough Economic Times? 7/3/2023

    See the answer from Charlene Banard, the former EVP, chief technical officer at Atara Biotherapeutics.